Invo Bioscience Inc (INVO)

$0.71

+0.01

(+1.84%)▲

Market is closed - opens 7 PM, 16 Sep 2024

Performance

  • $0.70
    $0.74
    $0.71
    downward going graph

    1.39%

    Downside

    Day's Volatility :5.23%

    Upside

    3.89%

    downward going graph
  • $0.50
    $3.50
    $0.71
    downward going graph

    29.58%

    Downside

    52 Weeks Volatility :85.71%

    Upside

    79.71%

    downward going graph

Returns

PeriodInvo Bioscience IncIndex (Russel 2000)
3 Months
-30.79%
0.0%
6 Months
-33.99%
0.0%
1 Year
-31.45%
0.0%
3 Years
-98.98%
-20.0%

Highlights

Market Capitalization
2.8M
Book Value
- $1.59
Earnings Per Share (EPS)
0.69
PE Ratio
1.03
Wall Street Target Price
20.0
Profit Margin
-122.8%
Operating Margin TTM
-103.61%
Return On Assets TTM
-26.57%
Return On Equity TTM
-14358.64%
Revenue TTM
5.8M
Revenue Per Share TTM
2.09
Quarterly Revenue Growth YOY
481.4%
Gross Profit TTM
535.3K
EBITDA
-4.6M
Diluted Eps TTM
0.69
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Sell
    0
    0%Buy
    50%Hold
    50%Sell
Based on 6 Wall street analysts offering stock ratings for Invo Bioscience Inc(by analysts ranked 0 to 5 stars)
Based on 6 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
3
3
3
Sell
3
3
3

Analyst Forecast

What analysts predicted

Upside of 2716.9%

Current $0.71
Target $20.00

Company Financials

FY18Y/Y Change
Revenue
494.4K
↑ 75.22%
Net Income
-3.1M
↑ 338.09%
Net Profit Margin
-622.22%
↓ 373.35%
FY19Y/Y Change
Revenue
1.5M
↑ 199.41%
Net Income
-2.2M
↓ 29.54%
Net Profit Margin
-146.43%
↑ 475.79%
FY20Y/Y Change
Revenue
1.0M
↓ 29.92%
Net Income
-8.3M
↑ 285.1%
Net Profit Margin
-804.73%
↓ 658.3%
FY21Y/Y Change
Revenue
4.2M
↑ 301.06%
Net Income
-6.7M
↓ 20.27%
Net Profit Margin
-159.97%
↑ 644.76%
FY22Y/Y Change
Revenue
822.2K
↓ 80.24%
Net Income
-10.9M
↑ 63.68%
Net Profit Margin
-1.3K%
↓ 1164.84%
FY23Y/Y Change
Revenue
3.0M
↑ 267.38%
Net Income
-8.0M
↓ 26.24%
Net Profit Margin
-266.0%
↑ 1058.81%
Q1 FY23Q/Q Change
Revenue
278.1K
↑ 0.0%
Net Income
-2.8M
↑ 0.0%
Net Profit Margin
-994.83%
↑ 0.0%
Q2 FY23Q/Q Change
Revenue
315.9K
↑ 13.58%
Net Income
-2.2M
↓ 19.03%
Net Profit Margin
-709.24%
↑ 285.59%
Q3 FY23Q/Q Change
Revenue
974.9K
↑ 208.61%
Net Income
-1.2M
↓ 44.28%
Net Profit Margin
-128.06%
↑ 581.18%
Q4 FY23Q/Q Change
Revenue
1.4M
↑ 41.73%
Net Income
-2.0M
↑ 59.78%
Net Profit Margin
-144.37%
↓ 16.31%
Q1 FY24Q/Q Change
Revenue
1.6M
↑ 14.08%
Net Income
-1.6M
↓ 19.97%
Net Profit Margin
-101.28%
↑ 43.09%
Q2 FY24Q/Q Change
Revenue
1.8M
↑ 16.51%
Net Income
-2.2M
↑ 40.63%
Net Profit Margin
-122.25%
↓ 20.97%
FY18Y/Y Change
Total Assets
777.3K
↑ 191.78%
Total Liabilities
3.5M
↓ 33.41%
FY19Y/Y Change
Total Assets
1.8M
↑ 130.98%
Total Liabilities
5.5M
↑ 57.33%
FY20Y/Y Change
Total Assets
10.9M
↑ 509.72%
Total Liabilities
5.2M
↓ 5.53%
FY21Y/Y Change
Total Assets
10.5M
↓ 4.39%
Total Liabilities
3.2M
↓ 39.36%
FY22Y/Y Change
Total Assets
4.1M
↓ 60.79%
Total Liabilities
5.1M
↑ 61.02%
FY23Y/Y Change
Total Assets
20.9M
↑ 409.0%
Total Liabilities
20.0M
↑ 293.5%
Q1 FY23Q/Q Change
Total Assets
4.1M
↑ 0.0%
Total Liabilities
5.1M
↑ 0.0%
Q2 FY23Q/Q Change
Total Assets
6.6M
↑ 61.78%
Total Liabilities
8.3M
↑ 64.22%
Q3 FY23Q/Q Change
Total Assets
19.5M
↑ 193.36%
Total Liabilities
19.1M
↑ 128.94%
Q4 FY23Q/Q Change
Total Assets
20.9M
↑ 7.25%
Total Liabilities
20.0M
↑ 4.67%
Q1 FY24Q/Q Change
Total Assets
18.3M
↓ 12.3%
Total Liabilities
18.3M
↓ 8.44%
Q2 FY24Q/Q Change
Total Assets
18.0M
↓ 1.56%
Total Liabilities
16.7M
↓ 8.95%
FY18Y/Y Change
Operating Cash Flow
-653.0K
↑ 260.22%
Investing Cash Flow
-19.4K
↑ 0.0%
Financing Cash Flow
858.9K
↑ 1472.27%
FY19Y/Y Change
Operating Cash Flow
1.4M
↓ 309.89%
Investing Cash Flow
-114.7K
↑ 491.27%
Financing Cash Flow
-229.5K
↓ 126.72%
FY20Y/Y Change
Operating Cash Flow
-4.8M
↓ 448.42%
Investing Cash Flow
-187.3K
↑ 63.25%
Financing Cash Flow
13.8M
↓ 6123.39%
FY21Y/Y Change
Operating Cash Flow
-6.0M
↑ 26.28%
Investing Cash Flow
-2.2M
↑ 1050.05%
Financing Cash Flow
3.8M
↓ 72.72%
FY22Y/Y Change
Operating Cash Flow
-6.6M
↑ 9.51%
Investing Cash Flow
-81.2K
↓ 96.23%
Financing Cash Flow
1.1M
↓ 71.1%
Q1 FY23Q/Q Change
Operating Cash Flow
-1.0M
↑ 0.0%
Investing Cash Flow
-8.4K
↓ 198.42%
Financing Cash Flow
800.0K
↑ 0.0%

Technicals Summary

Sell

Neutral

Buy

Invo Bioscience Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Invo Bioscience Inc
Invo Bioscience Inc
-20.27%
-33.99%
-31.45%
-98.98%
-98.83%
Stryker Corporation
Stryker Corporation
11.29%
4.11%
25.51%
34.51%
71.98%
Boston Scientific Corp.
Boston Scientific Corp.
9.02%
24.6%
57.43%
85.75%
98.64%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
3.04%
-26.61%
-7.43%
-43.34%
-4.43%
Abbott Laboratories
Abbott Laboratories
5.92%
-2.06%
13.4%
-8.38%
39.64%
Medtronic Plc
Medtronic Plc
10.11%
6.65%
9.81%
-31.08%
-17.47%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Invo Bioscience Inc
Invo Bioscience Inc
1.03
1.03
NA
0.0
-143.59
-0.27
NA
-1.59
Stryker Corporation
Stryker Corporation
41.32
41.32
2.72
12.0
0.19
0.07
0.01
51.86
Boston Scientific Corp.
Boston Scientific Corp.
67.73
67.73
2.05
2.41
0.09
0.05
NA
13.85
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
26.87
26.87
3.25
2.66
0.22
0.12
NA
12.35
Abbott Laboratories
Abbott Laboratories
36.72
36.72
4.25
4.66
0.14
0.06
0.02
22.6
Medtronic Plc
Medtronic Plc
30.3
30.3
1.67
5.2
0.08
0.04
0.03
37.39
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Invo Bioscience Inc
Invo Bioscience Inc
Sell
$2.8M
-98.83%
1.03
-122.8%
Stryker Corporation
Stryker Corporation
Buy
$141.1B
71.98%
41.32
16.12%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$122.7B
98.64%
67.73
12.0%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$41.1B
-4.43%
26.87
23.74%
Abbott Laboratories
Abbott Laboratories
Buy
$202.5B
39.64%
36.72
13.65%
Medtronic Plc
Medtronic Plc
Buy
$115.4B
-17.47%
30.3
12.06%

Insights on Invo Bioscience Inc

  • Increasing Revenue

    Revenue is up for the last 9 quarters, 146.13K → 1.83M (in $), with an average increase of 23.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -1.59M → -2.24M (in $), with an average decrease of 40.6% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 57.4% return, outperforming this stock by 88.9%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 85.8% return, outperforming this stock by 184.8%

Institutional Holdings

  • Vanguard Group Inc

    1.38%

  • Geode Capital Management, LLC

    0.84%

  • TWO SIGMA SECURITIES, LLC

    0.41%

  • Virtu Financial LLC

    0.32%

  • UBS Group AG

    0.21%

  • Tower Research Capital LLC

    0.18%

Company Information

with the invocell and invo procedure, invo bioscience allows more and more patients to now receive safe, effective and affordable infertility treatment.

Organization
Invo Bioscience Inc
Employees
25
CEO
Mr. Steven M. Shum
Industry
Miscellaneous

Discover More

FAQs